<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Enveric Biosciences, Inc. — News on 6ix</title>
<link>https://6ix.com/company/enveric-biosciences-inc</link>
<description>Latest news and press releases for Enveric Biosciences, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:33:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/enveric-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835638b78dffbe2df0ef4b5.webp</url>
<title>Enveric Biosciences, Inc.</title>
<link>https://6ix.com/company/enveric-biosciences-inc</link>
</image>
<item>
<title>Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/lakewood-amedex-biotherapeutics-appoints-joseph-tucker-phd-to-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/lakewood-amedex-biotherapeutics-appoints-joseph-tucker-phd-to-board-of-directors-1</guid>
<pubDate>Tue, 28 Apr 2026 11:33:00 GMT</pubDate>
<description>Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (Nasdaq: ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step i</description>
</item>
<item>
<title>Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-to-participate-in-a-panel-discussion-at-needhams-virtual-psychedelics-forum</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-to-participate-in-a-panel-discussion-at-needhams-virtual-psychedelics-forum</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 21, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will participate in a panel discussion at Needham’s upcoming Virtual Psychedelics Forum. The panel, "Beyond TRD (Treatment-Resistant Depression): Non-Hallucinogens and New Indications," is scheduled for M</description>
</item>
<item>
<title>Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-closing-of-up-to-dollar139-million-private-placement-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-closing-of-up-to-dollar139-million-private-placement-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Fri, 17 Apr 2026 22:28:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 17, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to a</description>
</item>
<item>
<title>Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-up-to-dollar139-million-private-placement-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-up-to-dollar139-million-private-placement-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Fri, 17 Apr 2026 00:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 17, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to an aggregate of 2,222,223 shares of common stock and</description>
</item>
<item>
<title>Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-secures-new-us-patent-for-its-evm301-series-of-drug-candidates</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-secures-new-us-patent-for-its-evm301-series-of-drug-candidates</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Patent provides added depth to Enveric’s EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of</description>
</item>
<item>
<title>Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-fourth-quarter-and-fiscal-year-ended-2025</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-fourth-quarter-and-fiscal-year-ended-2025</guid>
<pubDate>Fri, 27 Mar 2026 21:40:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 27, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today provided a corporate update following the filing of its 10-K on Friday, March 27, 2026, which reported financial results for the fourth quarter and year ended December 31, 2025.</description>
</item>
<item>
<title>Enveric Biosciences Announces Registration of Five Trademarks</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-registration-of-five-trademarks</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-registration-of-five-trademarks</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric”</description>
</item>
<item>
<title>Enveric Biosciences Announces Withdrawal of Petition Against Its Patent</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-withdrawal-of-petition-against-its-patent</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-withdrawal-of-petition-against-its-patent</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>As a result of this action, there are no remaining challenges currently pending against Enveric’s patent CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric</description>
</item>
<item>
<title>Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-reports-eb-003-bret-receptor-engagement-assay-data</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-reports-eb-003-bret-receptor-engagement-assay-data</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., February 19, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activatio</description>
</item>
<item>
<title>Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-expands-collaboration-totec-130000550</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-expands-collaboration-totec-130000550</guid>
<pubDate>Thu, 29 Jan 2026 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., January 29, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. ("TOTEC") its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology ("Aries"), is advancing the commercialization o</description>
</item>
<item>
<title>Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-closing-1-220000410</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-closing-1-220000410</guid>
<pubDate>Wed, 28 Jan 2026 22:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., January 28, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share. In a concurrent private placement, t</description>
</item>
<item>
<title>Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-1-5-130000810</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-1-5-130000810</guid>
<pubDate>Wed, 28 Jan 2026 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., January 28, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private</description>
</item>
<item>
<title>Enveric Biosciences Announces Patent Issuance</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-patent-issuance-130000715</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-patent-issuance-130000715</guid>
<pubDate>Mon, 29 Dec 2025 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., December 29, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives" (the "‘179 patent"), with claims to compositions and methods of treatment for novel molecules with the potential to be develope</description>
</item>
<item>
<title>Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-closing-exercise-214600414</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-closing-exercise-214600414</guid>
<pubDate>Fri, 12 Dec 2025 21:46:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., December 12, 2025--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, re</description>
</item>
<item>
<title>Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-exercise-warrants-184300324</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-exercise-warrants-184300324</guid>
<pubDate>Thu, 11 Dec 2025 18:43:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., December 11, 2025--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.9</description>
</item>
<item>
<title>Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-receives-notice-allowance-130000286</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-receives-notice-allowance-130000286</guid>
<pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., December 09, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.</description>
</item>
<item>
<title>Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-present-participate-panel-130000475</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-present-participate-panel-130000475</guid>
<pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., December 04, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during "J.P. Morgan Week 2026" in San Francisco. Additionally, Enveric will attend Biotech Showcase 2026, which is</description>
</item>
<item>
<title>Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-receives-fourth-notice-130000113</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-receives-fourth-notice-130000113</guid>
<pubDate>Wed, 26 Nov 2025 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., November 26, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM401 Series of molecules being developed as potential treatments for mental health disorders.</description>
</item>
<item>
<title>Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-reports-third-quarter-210500697</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-reports-third-quarter-210500697</guid>
<pubDate>Fri, 14 Nov 2025 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., November 14, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update.</description>
</item>
<item>
<title>Enveric Biosciences Announces Reverse Stock Split</title>
<link>https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-reverse-stock-120000936</link>
<guid isPermaLink="true">https://6ix.com/company/enveric-biosciences-inc/news/enveric-biosciences-announces-reverse-stock-120000936</guid>
<pubDate>Thu, 23 Oct 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., October 23, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 12 pre-split shares. The reverse stock split will become effective at 8:00 a.m., New York time, on Tuesday, October 28, 2025. Enveric’s co</description>
</item>
</channel>
</rss>